(MedPage Today) — CHICAGO — For extended anticoagulation after venous thromboembolism (VTE) in patients with active cancer, a lower dose of apixaban (Eliquis) was just as effective as a higher dose — and safer, the API-CAT randomized trial…
Source link : https://www.medpagetoday.com/meetingcoverage/acc/114876
Author :
Publish date : 2025-03-29 14:30:00
Copyright for syndicated content belongs to the linked Source.
